Sepsis is a clinical condition suffered by patients following infection or injury. It affects up to 30 million people per year, causing six million deaths worldwide on an annual basis. It is estimated to cost around $85 billion annually. It is not easy to diagnose sepsis or septic shock (SS), and predicting how a patient’s condition will evolve (prognosis) is still a challenge for modern medicine.
- To develop the “HistShock Kit” to provide an early diagnosis and precise prognosis for sepsis and SS, which is crucial to choose the best treatment option for the patient’s survival.
Problem to Solve
Sepsis is a global healthcare problem and the primary cause of death mainly due to infection, mostly bacterial. Moreover, mortality rates increase 9% every year. Current biomarkers for sepsis management show limitations in terms of both the diagnosis and prognosis of affected patients. There is an urgent need for new biomarkers to detect sepsis and SS with greater accuracy, at a lower cost, and with greater sensitivity.
A clinical routine in hospitals dealing with sepsis involves carrying out SOFA clinical score and supported by a procalcitonin test. However, this test has some limitations when distinguishing sepsis from other inflammatory conditions, and when predicting the patient’s prognosis. HistShock detects circulating histones, which are produced when the organism recognises an infection. These levels rise when tissues are damaged by sepsis progression, making this biomarker a good predictor of the severity and prognosis of the disease.
Level of Innovation
HistShock detects circulating histones using a mass spectrometry-based method. It has been tested in a small-scale clinical trial with plasma samples, improving on the sensitivity of current methods for SS diagnosis.